⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187895 | 0.61 | — | — | |
| SCHEMBL121560 | 0.58 | — | — | |
| SCHEMBL363405 | 0.56 | — | — | |
| SCHEMBL4647958 | 0.55 | — | — | |
| SCHEMBL29452760 | 0.54 | — | — | |
| SCHEMBL194088 | 0.52 | — | — | |
| SCHEMBL27468564 | 0.52 | — | — | |
| SCHEMBL29969 | 0.52 | — | — | |
| SCHEMBL2121178 | 0.50 | — | — | |
| SCHEMBL27909092 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | claimed |
| EP-2238127-B1 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-15 | — | — | EP | claimed |
| US-20110039829-A1 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | claimed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | claimed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | claimed |
| EP-2238127-A2 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | claimed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | claimed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | claimed |
| WO-2009080227-A2 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | claimed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | claimed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | claimed |
| US-6465462-B1 | COGNITION ENHANCEMENT FOR DEMENTING ILLNESSES SUCH AS ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. | 2002-10-15 | — | — | US | claimed |
| US-20240231224-A9 | HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF | LAM RESEARCH CORPORATION | 2024-07-11 | — | — | US | disclosed |
| WO-2024137876-A2 | SURFACE MODIFICATION OF METAL CATALYSTS WITH HYDROPHOBIC LIGANDS OR IONOMERS | TWELVE BENEFIT CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240200208-A1 | CO2 PURIFICATION AND REDUCTION SYSTEMS | SUMITOMO MITSUI BANKING CORPORATION | 2024-06-20 | — | — | US | disclosed |
| US-20240192590-A1 | APPARATUS AND PROCESS FOR EUV DRY RESIST SENSITIZATION BY GAS PHASE INFUSION OF A SENSITIZER | LAM RESEARCH CORPORATION | 2024-06-13 | — | — | US | disclosed |
| WO-2008129380-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1956009-A1 | AROMATIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2006098342-A1 | PIPERAZINYL COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2006-09-21 | — | — | WO | disclosed |